Respiratory Syncytial Virus

Multiplex respiratory virus testing enhances clinical decision-making for RSV in community hospitals.

Low RSV vaccination rates among older adults in the US highlight missed opportunities for reducing hospitalizations and health care costs.

Older adults face heightened risks from RSV due to declining immunity and chronic conditions, making vaccination crucial for prevention and health.

A recent study highlights the AOV dual-chamber system as a faster, safer option for RSV vaccine reconstitution, enhancing efficiency for health care providers.

RSV vaccination shows promise in reducing cardiorespiratory hospitalizations among older adults, highlighting potential heart and lung health benefits.

A single dose of an RSV vaccine significantly reduces hospitalization risk for older adults, offering protection for 2 seasons against severe infections.

Vaccination is vital for adults with heart disease to prevent severe respiratory illnesses like RSV, influenza, and COVID-19, enhancing overall health outcomes.

RSV causes a significant burden of acute respiratory infections in older adults.

RSVpreF was well tolerated in nonpregnant and pregnant individuals aged 18 years and older.

RSV vaccination rates among older adults remain low despite new vaccines, highlighting disparities in uptake and the need for targeted outreach.

RSV poses a serious risk to older adults in long-term care, highlighting the need for effective outbreak management and infection control strategies.

RSV hospitalization in older adults links to increased cardiovascular events, highlighting the need for vigilant monitoring and vaccination strategies.

RSV outbreaks pose significant risks globally, highlighting the urgent need for targeted vaccination and treatment strategies to protect vulnerable populations.

Immunocompromised patients, especially transplant recipients, face heightened RSV risks, leading to severe infections and complications.

Researchers unveil compounds that enhance cell death and boost antiviral responses, offering hope against RSV and other viral infections.

Recent research reveals that RSV and shingles vaccines significantly lower dementia risk, highlighting the potential benefits of AS01 adjuvants in vaccination.

A recent study reveals high RSV antibody levels in older adults, highlighting the importance of vaccination and natural infection for enhanced immunity.

New research highlights the significant health risks of respiratory syncytial virus (RSV) in older adults, emphasizing the need for effective vaccines and public health strategies.

Moderna's mRNA-1345 vaccine gains FDA approval, enhancing protection against RSV for high-risk adults aged 18 to 59 years, following earlier approvals for older populations.

New research analyzes human challenge infection studies to reveal insights on respiratory syncytial virus viral load and symptom dynamics, aiding treatment development.

New research highlights the significant cardiovascular risks associated with RSV, emphasizing the need for vaccination to protect vulnerable populations.

New research highlights the effectiveness and safety of RSV vaccines for older adults, revealing critical insights into vaccination benefits and risks.

Administration during peak vaccine effectiveness provides maximal protective benefit

A recent study highlights the promising immune response and safety of the Arexvy vaccine in lung transplant recipients, crucial for preventing RSV infections.

New research shows adults with RSV-ARI may face significantly higher mortality and health complications, emphasizing the need for targeted vaccination strategies.